Marius Hoeper, MD, offers expert perspectives on the recently FDA-approved sotatercept, focusing on its mechanism of action, potential cost implications, and potential advantages and disadvantages it ...

AJMC: Can you explain the etiology and progression of PAH and the importance of early diagnosis? HASSOUN: Pulmonary arterial hypertension (PAH) refers to World Health Organization (WHO) group 1 ...

To correct high blood pressure of the pulmonary artery, which can arise from congenital defects of the heart, an artificial heart ucan cost upwards of $190,000. Heart disease accounted for about one ...

Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.

A relatively new therapy used to treat pulmonary arterial hypertension in those with mild to moderate disease was found to be effective at preventing death in those with more advanced disease. Results ...

Credit: Merck. Winrevair is a first-in-class recombinant activin receptor type IIA-Fc fusion protein designed to bind to activin A and other TGF-β superfamily ligands. The Food and Drug Administration ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

The FDA has approved YUTREPIA™ (treprostinil) inhalation powder, developed by Liquidia Corporation, as a treatment option for adults with pulmonary arterial hypertension (PAH) and pulmonary ...

Pulmonary arterial hypertension (PAH) is a rare condition that's difficult to treat. The hallmarks of the disease—narrowing of the arterioles and capillaries that deliver blood to the lungs—force the ...

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries that go from your heart to your lungs. It happens when these arteries become narrow or blocked, making it harder ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved sotatercept (Winrevair, Merck Sharp & Dohme) as a new treatment to improve exercise capacity in patients with pulmonary ...